Globaler Markt für Fieberblasenbehandlungen (für HSV-1-Virus) – Branchentrends und Prognose bis 2031

Bericht anpassenBericht anpassen Jetzt kaufen Jetzt kaufen Kostenloser Beispielbericht Kostenloser Beispielbericht
Home Pharmaceutical Global Cold Sore Treatment For Hsv 1 Virus Market
Inhaltsverzeichnis anfordernInhaltsverzeichnis anfordern Mit Analyst sprechen Mit Analyst sprechen Jetzt kaufenJetzt kaufen Vor dem Kauf anfragen Vorher anfragen Kostenloser Beispielbericht Kostenloser Beispielbericht

Globaler Markt für Fieberblasenbehandlungen (für HSV-1-Virus) – Branchentrends und Prognose bis 2031

  • Pharmaceutical
  • Publish Reports
  • May 2024
  • Global
  • 350 Seiten
  • Anzahl der Tabellen: 736
  • Anzahl der Abbildungen: 56
Jetzt kaufen Jetzt kaufen

Global Cold Sore Treatment For Hsv 1 Virus Market

Marktgröße in Milliarden USD

CAGR :  % Diagram

Diagramm Prognosezeitraum
 2024 –2031
Diagramm Marktgröße (Basisjahr)
 USD 927.29 Million
Diagramm Marktgröße (Prognosejahr)
 USD 1,501.88 Million
Diagramm CAGR
 %
Diagramm Wichtige Marktteilnehmer
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5
Anfrage zur Freischaltung

>Globaler Markt für die Behandlung von Fieberblasen (für das HSV-1-Virus), nach Behandlungstyp (Medikamente, angewandte Produkte, Fieberblasenpflaster und andere (nicht medikamentöse Produkte)), Verabreichungsweg (oral, topisch und andere), Kaufmodus (rezeptfrei und verschreibungspflichtig), Stammtyp (Herpes-simplex-Virus Typ 1 und Herpes-simplex-Virus Typ 2), Medikamententyp (Generika und Marken), Bevölkerungstyp (Erwachsene, Kinder und Geriatrie), Geschlecht (weiblich und männlich), Endbenutzer (häusliche Gesundheitspflege, Krankenhäuser, Fachkliniken und andere), Vertriebskanal (direkte Ausschreibungen, Einzelhandelsverkäufe und andere) – Branchentrends und Prognose bis 2031.

Markt für die Behandlung von Fieberbläschen (für das HSV-1-Virus)

Marktanalyse und -größe für die Behandlung von Fieberbläschen (für das HSV-1-Virus)

Es wird erwartet, dass der globale Markt für die Behandlung von Fieberblasen (gegen das HSV-1-Virus) im Prognosezeitraum von 2024 bis 2031 an Marktwachstum gewinnt.

Der globale Markt für Lippenherpesbehandlungen (für das HSV-1-Virus) wird durch die hohe Verbreitung von HSV-1- und H11-Viren angetrieben und ist ein wichtiger Treiber des globalen Marktes für Lippenherpesbehandlungen (für das HSV-1-Virus). HSV-1 ist weit verbreitet und infiziert schätzungsweise 67 % der Weltbevölkerung unter 50 Jahren. Ebenso sind H11-Infektionen bei Geflügel häufig und werden gelegentlich auf den Menschen übertragen.

Markt für die Behandlung von Fieberbläschen (für das HSV-1-Virus)Markt für die Behandlung von Fieberbläschen (für das HSV-1-Virus)

Diese Prävalenz treibt die Nachfrage nach wirksamen Behandlungen voran. Menschen mit HSV-1 oder H11 leiden häufig unter wiederkehrenden Lippenherpes-Ausbrüchen, die schmerzhaft und unansehnlich sein können. Dies führt zu einer starken Nachfrage der Verbraucher nach Behandlungen, die die Symptome lindern, die Häufigkeit der Ausbrüche verringern und die Übertragung verhindern können. Veränderte Lebensstile, darunter erhöhter Stress, Müdigkeit und Sonneneinstrahlung, können Ausbrüche auslösen. Die alternde Bevölkerung ist außerdem anfälliger für Lippenherpes, was zu höheren Infektionsraten beiträgt.

Data Bridge Market Research analysiert, dass der globale Markt für die Behandlung von Fieberblasen (gegen das HSV-1-Virus) im Prognosezeitraum von 2024 bis 2031 mit einer durchschnittlichen jährlichen Wachstumsrate (CAGR) von 6,6 % wächst und von 927,29 Millionen US-Dollar im Jahr 2023 auf 1.501,88 Millionen US-Dollar im Jahr 2031 ansteigen dürfte.

Berichtsmetrik

Details

Prognosezeitraum

2024 bis 2031

Basisjahr

2023

Historische Jahre

2022 (Anpassbar 2016–2021)

Quantitative Einheiten

Umsatz in Mio. USD

Abgedeckte Segmente

Behandlungsart (Medikamente, angewandte Produkte, Pflaster gegen Fieberblasen und andere (nicht medikamentöse Produkte)), Verabreichungsweg (oral, topisch und andere), Kaufmethode (rezeptfrei und verschreibungspflichtig ), Stammtyp (Herpes-simplex-Virus Typ 1 und Herpes-simplex-Virus Typ 2), Medikamententyp (Generika und Markenprodukte), Bevölkerungstyp (Erwachsene, Kinder und Geriatrie), Geschlecht (weiblich und männlich), Endnutzer ( häusliche Gesundheitspflege , Krankenhäuser, Fachkliniken und andere), Vertriebskanal (direkte Ausschreibungen, Einzelhandelsverkauf und andere)

Abgedeckte Länder

USA, Kanada und Mexiko, Großbritannien, Deutschland, Frankreich, Spanien, Italien, Belgien, Russland, Schweiz, Niederlande, Türkei und übriges Europa, China, Australien, Japan, Indien, Singapur, Südkorea, Malaysia, Thailand, Indonesien, Philippinen und übriger Asien-Pazifik-Raum, Brasilien, Argentinien und übriges Südamerika, Südafrika, Ägypten, Saudi-Arabien, Vereinigte Arabische Emirate und übriger Naher Osten und Afrika

Abgedeckte Marktteilnehmer

Fresenius SE & Co. KGaA, Zydus Pharmaceuticals, Inc., Teva Pharmaceuticals Industries Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Quantum Health, GSK plc., Haleon Group of Companies, Church & Dwight Co., Inc., Hikma Pharmaceuticals PLC, Viatris Inc., Carma Labs Inc., URGO MEDICAL, Apotex Inc., Amneal Pharmaceuticals LLC, Blistex Inc., FOCUS CONSUMER HEALTHCARE, Hetero Healthcare Limited, Amparo medical Technologies und Devirex AG unter anderem

Marktdefinition

HSV-1 oder Herpes-simplex-Virus Typ 1 ist ein weit verbreitetes Virus, das Fieberbläschen, auch Fieberblasen genannt, auf den Lippen und um den Mund herum verursacht. Diese Wunden sind mit Flüssigkeit gefüllte Blasen, die schmerzhaft sein können und etwa 7-10 Tage anhalten können.

Zur Behandlung von Fieberbläschen werden in der Regel antivirale Medikamente wie Aciclovir, Famciclovir oder Valaciclovir eingesetzt, die die Schwere und Dauer der Ausbrüche verringern können. Auch rezeptfreie Cremes und Salben, beispielsweise solche mit Docosanol oder Benzylalkohol , können die Symptome lindern. Wenn Sie die betroffene Stelle sauber halten und Auslöser wie Stress oder Sonneneinstrahlung vermeiden, können Sie Ausbrüchen vorbeugen.

Globale Marktdynamik für Fieberblasenbehandlung (für HSV-1-Virus)

In diesem Abschnitt geht es um das Verständnis der Markttreiber, Vorteile, Chancen, Einschränkungen und Herausforderungen. All dies wird im Folgenden ausführlich erläutert:

Treiber

  • Zunehmende Prävalenz von Fieberblaseninfektionen

Die zunehmende Verbreitung von Lippenherpes-Infektionen, die durch veränderte Lebensstile, eine alternde Bevölkerung, ein gesteigertes Bewusstsein und die Globalisierung verursacht wird, ist ein wichtiger Treiber des globalen Marktes für Lippenherpes-Behandlungen (für das HSV-1-Virus). Dieser Trend wird sich voraussichtlich fortsetzen und zu weiteren Innovationen und der Entwicklung neuer Behandlungsmöglichkeiten für Personen führen, die von diesen Infektionen betroffen sind.

  • Wachsendes Bewusstsein für Symptome und Behandlungsmöglichkeiten von Fieberbläschen

Die zunehmende Verfügbarkeit von Informationen über Fieberbläschen über verschiedene Medienkanäle wie das Internet, soziale Medien und Gesundheitskampagnen hat das Bewusstsein für die Anzeichen und Symptome von Fieberbläschen geschärft. Dieses gesteigerte Bewusstsein hat dazu geführt, dass mehr Menschen medizinischen Rat und eine Behandlung für ihre Fieberbläschen suchen, was wiederum das Marktwachstum vorangetrieben hat.

Markt für die Behandlung von Fieberbläschen (für das HSV-1-Virus)

Gelegenheit

  • Immer mehr Fortschritte bei der Behandlung von Fieberblaseninfektionen

Durchbrüche bei der Behandlung von Fieberbläschen (HSV-1) und Herpes zoster (Varizella-Zoster-Virus) haben zur Entwicklung wirksamerer antiviraler Medikamente mit weniger Nebenwirkungen geführt. Innovative Verabreichungssysteme wie liposomale Formulierungen haben die Wirksamkeit der Behandlung und die Compliance der Patienten verbessert.

Einschränkung/Herausforderung

  • Zunehmende Komplexität der Impfstoffentwicklung

Die Entwicklung eines Impfstoffs zur Behandlung von Fieberbläschen, die durch das HSV-1-Virus verursacht werden, ist mit erheblichen Hindernissen verbunden. Eine dieser Herausforderungen ist die Fähigkeit des Virus, in Nervenganglien eine Latenzzeit zu etablieren, was es schwierig macht, es mit Impfstoffen anzugreifen, da es inaktiv in inaktiven Virusreservoirs verharrt. Darüber hinaus erschweren die Immunfluchtmechanismen von HSV-1 die Induktion einer robusten und anhaltenden Immunantwort durch Impfung. Trotz dieser Herausforderungen sind kontinuierliche Forschung und Innovation von entscheidender Bedeutung, um die Impfstoffentwicklung voranzutreiben und die Belastung durch HSV-1-Infektionen weltweit zu verringern.

Jüngste Entwicklungen

  • Im August 2019 berichtete Sun Pharmaceutical Industries Ltd., dass eine ihrer Tochtergesellschaften einer Tochtergesellschaft der China Medical System Holding Ltd. eine Lizenzvereinbarung zur Entwicklung und Vermarktung von 7 Generika in China erteilt hat. Diese Vereinbarung hilft dem Unternehmen, sein Geschäft auszubauen und das Produktprofil zu stärken.
  • Im November 2020 hatte Amneal Pharmaceuticals LLC die FDA-Zulassung seines Abbreviated New Drug Application (ANDA) für Acyclovir Cream, 5 % erklärt. Es handelt sich um die generische Version von Zovirax zur Behandlung von Herpes labialis bei Jugendlichen. Die Initiative des Unternehmens würde zu einer verstärkten Verbreitung des Produkts, einer Steigerung der Markenbekanntheit und steigenden Umsätzen führen. Dies würde zu einem positiven Marktwachstum führen.
  • Im August 2020 schloss GSK die Übernahme von Affinivax, Inc. ab und gab bekannt, dass es die Übernahme von Affinivax, Inc. (Affinivax) mit Sitz in Cambridge, Massachusetts, abgeschlossen hat, einem biopharmazeutischen Unternehmen in der klinischen Phase. Pneumokokken-Impfstoffe der nächsten Generation sind die am weitesten entwickelten einer neuen Impfstoffklasse, die Affinivax anführt.

Globaler Marktumfang für Fieberblasenbehandlungen (für HSV-1-Virus)

Der globale Markt für Lippenherpesbehandlungen (für das HSV-1-Virus) ist in neun wichtige Segmente unterteilt, basierend auf Behandlungsart, Verabreichungsweg, Kaufmethode, Stammtyp, Arzneimitteltyp, Bevölkerungstyp, Geschlecht, Endverbraucher und Vertriebskanal. Das Wachstum zwischen den Segmenten hilft Ihnen bei der Analyse von Nischenwachstumsbereichen und Strategien zur Marktansprache und zur Bestimmung Ihrer wichtigsten Anwendungsbereiche und der Unterschiede in Ihren Zielmärkten.

Behandlungstyp

  • Medikamente
  • Eingesetzte Produkte
  • Pflaster gegen Fieberbläschen
  • Sonstiges (nicht medizinische Produkte)

Auf der Grundlage der Behandlungsart ist der globale Markt für die Behandlung von Fieberblasen (für das HSV-1-Virus) in Medikamente, angewandte Produkte, Fieberblasenpflaster und sonstige (nicht medikamentöse Produkte) segmentiert.

Verabreichungsweg

  • Oral
  • Aktuell
  • Sonstiges

Auf der Grundlage der Verabreichungsmethode ist der globale Markt für die Behandlung von Fieberblasen (gegen das HSV-1-Virus) in orale, topische und andere Mittel unterteilt.

Kaufart

  • Über den Ladentisch
  • Verschreibungspflichtige Medikamente

Auf der Grundlage der Kaufart ist der globale Markt für die Behandlung von Fieberblasen (gegen das HSV-1-Virus) in rezeptfreie und verschreibungspflichtige Medikamente segmentiert.

Belastungstyp

  • Herpes-simplex-Virus Typ 1
  • Herpes-simplex-Virus Typ 2

Auf der Grundlage des Stammtyps ist der globale Markt für die Behandlung von Fieberblasen (für das HSV-1-Virus) in Herpes-simplex-Virus Typ 1 und Herpes-simplex-Virus Typ 2 segmentiert.

Arzneimitteltyp

  • Generisch
  • Gebrandmarkt

Auf der Grundlage des Arzneimitteltyps ist der globale Markt für die Behandlung von Fieberblasen (gegen das HSV-1-Virus) in Generika und Markenprodukte segmentiert.

Bevölkerungstyp

  • Erwachsene
  • Pädiatrie
  • Geriatrie

Auf der Grundlage des Bevölkerungstyps ist der globale Markt für die Behandlung von Fieberblasen (gegen das HSV-1-Virus) in die Bereiche Erwachsene, Kinder und Geriatrie segmentiert.

Geschlecht

  • Weiblich
  • Männlich

Auf der Grundlage des Geschlechts ist der globale Markt für die Behandlung von Fieberblasen (gegen das HSV-1-Virus) in Frauen und Männer segmentiert.

Endbenutzer

  • Häusliche Gesundheitspflege
  • Krankenhäuser
  • Spezialkliniken
  • Sonstiges

Auf der Grundlage des Endverbrauchers ist der globale Markt für die Behandlung von Fieberblasen (für das HSV-1-Virus) in häusliche Pflege, Krankenhäuser, Fachkliniken und andere unterteilt.

Vertriebskanal

  • Direkte Ausschreibungen
  • Einzelhandelsumsätze
  • Sonstiges

Auf der Grundlage der Vertriebskanäle ist der globale Markt für die Behandlung von Fieberblasen (für das HSV-1-Virus) in Direktausschreibungen, Einzelhandelsverkäufe und Sonstiges segmentiert.

Markt für die Behandlung von Fieberbläschen (für das HSV-1-Virus)

Globale Marktanalyse/Einblicke zur Behandlung von Fieberblasen (für HSV-1-Virus)

Der globale Markt für die Behandlung von Fieberblasen (für das HSV-1-Virus) wird analysiert und Erkenntnisse und Trends in Bezug auf die Marktgröße werden bereitgestellt, basierend auf Behandlungstyp, Verabreichungsweg, Kaufmodus, Stammtyp, Arzneimitteltyp, Bevölkerungstyp, Geschlecht, Endverbraucher und Vertriebskanal wie oben erwähnt.

Die in diesem globalen Marktbericht zur Behandlung von Fieberblasen (für das HSV-1-Virus) abgedeckten Länder sind die USA, Kanada und Mexiko, Großbritannien, Deutschland, Frankreich, Spanien, Italien, Belgien, Russland, die Schweiz, die Niederlande, die Türkei und der Rest von Europa, China, Australien, Japan, Indien, Singapur, Südkorea, Malaysia, Thailand, Indonesien, die Philippinen und der Rest des asiatisch-pazifischen Raums, Brasilien, Argentinien und der Rest von Südamerika, Südafrika, Ägypten, Saudi-Arabien, die Vereinigten Arabischen Emirate und der Rest des Nahen Ostens und Afrikas.

Aufgrund von Faktoren wie der hohen Verbreitung von Lippenherpes, einer fortschrittlichen Gesundheitsinfrastruktur, einem hohen Verbraucherbewusstsein und hoher Kaufkraft, laufenden Forschungs- und Entwicklungsinitiativen, etablierten Marketing- und Vertriebsnetzwerken und einer geringeren Stigmatisierung der Patienten, die eine Behandlung in Anspruch nehmen möchten, wird erwartet, dass Nordamerika den globalen Markt für Lippenherpes-Behandlungen (gegen das HSV-1-Virus) dominieren wird.

Die USA werden voraussichtlich den nordamerikanischen Markt für Fieberblasenbehandlungen (gegen das HSV-1-Virus) dominieren. Grund dafür sind Faktoren wie die große Bevölkerung, die hohen Gesundheitsausgaben, das hochentwickelte Gesundheitssystem, die ausgedehnte Pharmaindustrie sowie das weitverbreitete Bewusstsein der Verbraucher für Fieberblasenbehandlungen und deren Zugang.

Deutschland dürfte den europäischen Markt für die Behandlung von Lippenherpes (gegen das HSV-1-Virus) dominieren, da das Land über eine hochentwickelte Gesundheitsinfrastruktur, eine große Verbrauchernachfrage nach Behandlungsmöglichkeiten für Lippenherpes, eine starke Pharmaindustrie, umfangreiche Forschungs- und Entwicklungsanstrengungen und gut etablierte Vertriebsnetze verfügt, was das Land zu einem Zentrum für Innovation und Zugänglichkeit bei der Behandlung von Lippenherpes macht.

Aufgrund seiner hohen Bevölkerungszahl, steigender Gesundheitsausgaben, expandierender Pharmaindustrie, wachsendem Verbraucherbewusstsein und steigender Nachfrage nach Behandlungsmöglichkeiten für Fieberbläschen, gepaart mit einer sich entwickelnden Gesundheitsinfrastruktur und einer steigenden Prävalenz von Fieberbläschen, wird China voraussichtlich den Markt für Behandlungen von Fieberbläschen (gegen das HSV-1-Virus) im asiatisch-pazifischen Raum dominieren.

Der Länderabschnitt des Berichts enthält auch einzelne marktbeeinflussende Faktoren und Änderungen der Marktregulierung, die die aktuellen und zukünftigen Trends des Marktes beeinflussen. Datenpunkte wie Downstream- und Upstream-Wertschöpfungskettenanalysen, technische Trends und Porters Fünf-Kräfte-Analyse sowie Fallstudien sind einige der Anhaltspunkte, die zur Prognose des Marktszenarios für einzelne Länder verwendet werden. Bei der Bereitstellung von Prognoseanalysen der Länderdaten werden auch die Präsenz und Verfügbarkeit globaler Marken und ihre Herausforderungen aufgrund großer oder geringer Konkurrenz durch lokale und inländische Marken sowie die Auswirkungen inländischer Zölle und Handelsrouten berücksichtigt.   

Markt für die Behandlung von Fieberbläschen (für das HSV-1-Virus)

Wettbewerbsumfeld und globale Fieberblasenbehandlung (für HSV-1-Virus) Marktanteilsanalyse

Die Wettbewerbslandschaft des globalen Marktes für Lippenherpesbehandlungen (für das HSV-1-Virus) bietet Details nach Wettbewerbern. Die enthaltenen Details sind Unternehmensübersicht, Unternehmensfinanzen, erzielter Umsatz, Marktpotenzial, Investitionen in Forschung und Entwicklung, neue Marktinitiativen, globale Präsenz, Produktionsstandorte und -einrichtungen, Produktionskapazitäten, Stärken und Schwächen des Unternehmens, Produkteinführung, Produktbreite und -umfang sowie Anwendungsdominanz. Die oben angegebenen Datenpunkte beziehen sich nur auf den Fokus der Unternehmen auf den globalen Markt für Lippenherpesbehandlungen (für das HSV-1-Virus).

Zu den wichtigsten Akteuren auf dem globalen Markt für die Behandlung von Fieberblasen (gegen das HSV-1-Virus) zählen unter anderem Fresenius SE & Co. KGaA, Zydus Pharmaceuticals, Inc., Teva Pharmaceuticals Industries Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Quantum Health, GSK plc., Haleon Group of Companies, Church & Dwight Co., Inc., Hikma Pharmaceuticals PLC, Viatris Inc., Carma Labs Inc., URGO MEDICAL, Apotex Inc., Amneal Pharmaceuticals LLC, Blistex Inc., FOCUS CONSUMER HEALTHCARE, Hetero Healthcare Limited, Amparo medical Technologies und Devirex AG.

SKU-

Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud

Sample Image Klicken Sie auf das Bild, um es zu vergrößern
  • Interaktives Datenanalyse-Dashboard
  • Unternehmensanalyse-Dashboard für Chancen mit hohem Wachstumspotenzial
  • Zugriff für Research-Analysten für Anpassungen und Abfragen
  • Konkurrenzanalyse mit interaktivem Dashboard
  • Aktuelle Nachrichten, Updates und Trendanalyse
  • Nutzen Sie die Leistungsfähigkeit der Benchmark-Analyse für eine umfassende Konkurrenzverfolgung
Demo anfordern

Inhaltsverzeichnis

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 MARKET APPLICATION COVERAGE GRID

2.8 PRODUCT LIFELINE CURVE

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER’S FIVE FORCES

5 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: REGULATIONS

5.1 REGULATION IN U.S.:

5.2 REGULATION IN CANADA:

5.3 REGULATION IN SPAIN:

5.4 REGULATION IN U.K.:

5.5 REGULATION IN INDIA

 

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 GROWING PREVALENCE OF COLD SORE INFECTION

6.1.2 GROWING AWARENESS ABOUT COLD SORE SYMPTOMS AND TREATMENT OPTIONS

6.1.3 IMPACT OF GENERIC DRUGS ON THE GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET

6.2 RESTRAINTS

6.2.1 DEVELOPMENT OF DRUG-RESISTANT STRAINS OF HSV-1 AND H11 VIRUSES

6.2.2 LACK OF CURATIVE TREATMENT FOR INFECTION

6.3 OPPORTUNITIES

6.3.1 RISING ADVANCEMENTS IN TREATMENTS FOR COLD SORE INFECTIONS

6.3.2 INCREASING ADOPTION OF TELEMEDICINE AND DIGITAL HEALTH SOLUTIONS

6.4 CHALLENGES

6.4.1 INCREASING COMPLEXITY OF VACCINE DEVELOPMENT

6.4.2 SIDE EFFECTS ASSOCIATED WITH MEDICATIONS IN TREATING COLD SORE

7 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE

7.1 OVERVIEW

7.2 MEDICATIONS

7.2.1 ANTIVIRAL AGENTS

7.2.2 ANALGESIC AGENTS

7.2.3 OTHERS

7.3 APPLIED PRODUCTS

7.3.1 BRANDED

7.3.2 GENERICS

7.4 COLD SORE PATCHES

7.4.1 SEMI OCCLUSIVE HYDROCOLLOID PATCH

7.4.2 FILM FORMING PATCH

7.5 OTHERS (NON MEDICATED PRODUCTS)

8 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION

8.1 OVERVIEW

8.2 ORAL

8.2.1 TABLETS

8.2.2 CAPSULES

8.2.3 OTHERS

 

8.3 TOPICAL

8.3.1 CREAM

8.3.2 LIP BALM

8.3.3 OTHERS

8.4 OTHERS

9 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE

9.1 OVERVIEW

9.2 OVER THE COUNTER

9.3 PRESCRIPTION DRUG

10 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY STRAIN TYPE

10.1 OVERVIEW

10.2 HERPES SIMPLEX TYPE 1 VIRUS

10.3 HERPES SIMPLEX TYPE 2 VIRUS

11 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY DRUG TYPE

11.1 OVERVIEW

11.2 GENERIC

11.3 BRANDED

12 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY POPULATION TYPE

12.1 OVERVIEW

12.2 ADULTS

12.3 PEDIATRICS

12.4 GERIATRICS

13 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY GENDER

13.1 OVERVIEW

13.2 FEMALE

13.3 MALE

14 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY END USER

14.1 OVERVIEW

14.2 HOME HEALTHCARE

14.3 HOSPITALS

14.4 SPECIALTY CLINICS

14.5 OTHERS

15 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL

15.1 OVERVIEW

15.2 DIRECT TENDERS

15.3 RETAIL SALES

16 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION

16.1 OVERVIEW

16.2 NORTH AMERICA

16.2.1 U.S.

16.2.2 CANADA

16.2.3 MEXICO

16.3 EUROPE

16.3.1 GERMANY

16.3.2 FRANCE

16.3.3 U.K.

16.3.4 ITALY

16.3.5 SPAIN

16.3.6 RUSSIA

16.3.7 SWITZERLAND

16.3.8 NETHERLAND

16.3.9 TURKEY

16.3.10 BELGIUM

16.3.11 REST OF EUROPE

16.4 ASIA-PACIFIC

16.4.1 CHINA

16.4.2 JAPAN

16.4.3 INDIA

16.4.4 AUSTRALIA

16.4.5 SOUTH KOREA

16.4.6 SINGAPORE

16.4.7 MALAYSIA

16.4.8 PHILIPPINES

16.4.9 INDONESIA

16.4.10 THAILAND

16.4.11 REST OF ASIA-PACIFIC

 

16.5 SOUTH AMERICA

16.5.1 BRAZIL

16.5.2 ARGENTINA

16.5.3 REST OF SOUTH AMERICA

16.6 MIDDLE EAST AND AFRICA

16.6.1 SOUTH AFRICA

16.6.2 EGYPT

16.6.3 SAUDI ARABIA

16.6.4 U.A.E.

17 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: GLOBAL

17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

17.3 COMPANY SHARE ANALYSIS: EUROPE

17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

18 SWOT ANALYSIS

19 COMPANY PROFILE

19.1 FRESENIUS SE & CO. KGAA

19.1.1 COMPANY SNAPSHOT

19.1.2 REVENUE ANALYSIS

19.1.3 COMPANY SHARE ANALYSIS

19.1.4 PRODUCT PORTFOLIO

19.1.5 RECENT DEVELOPMENT

19.2 ZYDUS PHARMACEUTICALS INC.

19.2.1 COMPANY SNAPSHOT

19.2.2 COMPANY SHARE ANALYSIS

19.2.3 PRODUCT PORTFOLIO

19.2.4 RECENT DEVELOPMENT

19.3 TEVA PHARMACEUTICAL INDUSTRIES LTD.

19.3.1 COMPANY SNAPSHOT

19.3.2 REVENUE ANALYSIS

19.3.3 COMPANY SHARE ANALYSIS

19.3.4 PRODUCT PORTFOLIO

19.3.5 RECENT DEVELOPMENT

 

19.4 NOVARTIS AG

19.4.1 COMPANY SNAPSHOT

19.4.2 REVENUE ANALYSIS

19.4.3 COMPANY SHARE ANALYSIS

19.4.4 PRODUCT PORTFOLIO

19.4.5 RECENT DEVELOPMENT

19.5 SUN PHARMACEUTICALS INDUSTRIES LIMITED

19.5.1 COMPANY SNAPSHOT

19.5.2 REVENUE ANALYSIS

19.5.3 COMPANY SHARE ANALYSIS

19.5.4 PRODUCT PORTFOLIO

19.5.5 RECENT DEVELOPMENT

19.6 AMNEAL PHARMACEUTICALS LLC

19.6.1 COMPANY SNAPSHOT

19.6.2 REVENUE ANALYSIS

19.6.3 PRODUCT PORTFOLIO

19.6.4 RECENT DEVELOPMENT

19.7 AMPARO MEDICAL TECHNOLOGIES

19.7.1 COMPANY SNAPSHOT

19.7.2 PRODUCT PORTFOLIO

19.7.3 RECENT DEVELOPMENT

19.8 APOTEX INC.

19.8.1 COMPANY SNAPSHOT

19.8.2 PRODUCT PORTFOLIO

19.8.3 RECENT DEVELOPMENT

19.9 BLISTEX INC.

19.9.1 COMPANY SNAPSHOT

19.9.2 PRODUCT PORTFOLIO

19.9.3 RECENT DEVELOPMENT

19.1 CARMA LABS INC.

19.10.1 COMPANY SNAPSHOT

19.10.2 PRODUCT PORTFOLIO

19.10.3 RECENT DEVELOPMENT

19.11 CHURCH & DWIGHT CO., INC.

19.11.1 COMPANY SNAPSHOT

19.11.2 REVENUE ANALYSIS

19.11.3 PRODUCT PORTFOLIO

19.11.4 RECENT DEVELOPMENT

 

19.12 DEVIREX AG

19.12.1 COMPANY SNAPSHOT

19.12.2 PRODUCT PORTFOLIO

19.12.3 RECENT DEVELOPMENT

19.13 FOCUS CONSUMER HEALTHCARE

19.13.1 COMPANY SNAPSHOT

19.13.2 PRODUCT PORTFOLIO

19.13.3 RECENT DEVELOPMENT

19.14 GSK PLC.

19.14.1 COMPANY SNAPSHOT

19.14.2 REVENUE ANALYSIS

19.14.3 PRODUCT PORTFOLIO

19.14.4 RECENT DEVELOPMENT

19.15 HALEON GROUP OF COMPANIES

19.15.1 COMPANY SNAPSHOT

19.15.2 REVENUE ANALYSIS

19.15.3 PRODUCT PORTFOLIO

19.15.4 RECENT DEVELOPMENT

19.16 HETERO HEALTH CARE LIMITED

19.16.1 COMPANY SNAPSHOT

19.16.2 PRODUCT PORTFOLIO

19.16.3 RECENT DEVELOPMENT

19.17 HIKMA PHARMACEUTICALS PLC

19.17.1 COMPANY SNAPSHOT

19.17.2 REVENUE ANALYSIS

19.17.3 PRODUCT PORTFOLIO

19.17.4 RECENT DEVELOPMENT

19.18 QUANTUM HEALTH

19.18.1 COMPANY SNAPSHOT

19.18.2 PRODUCT PORTFOLIO

19.18.3 RECENT DEVELOPMENT

19.19 URGO MEDICAL

19.19.1 COMPANY SNAPSHOT

19.19.2 PRODUCT PORTFOLIO

19.19.3 RECENT DEVELOPMENT

19.2 VIATRIS INC.

19.20.1 COMPANY SNAPSHOT

19.20.2 REVENUE ANALYSIS

19.20.3 PRODUCT PORTFOLIO

19.20.4 RECENT DEVELOPMENT

20 QUESTIONNAIRE

21 RELATED REPORTS

Tabellenverzeichnis

TABLE 1 TREATMENT OF PEDIATRIC HSV INFECTIONS

TABLE 2 TREATMENT OPTIONS

TABLE 3 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 4 GLOBAL MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 5 GLOBAL MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 6 GLOBAL ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 7 GLOBAL ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 8 GLOBAL APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 9 GLOBAL APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 10 GLOBAL BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 11 GLOBAL APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 12 GLOBAL COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 13 GLOBAL COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 14 GLOBAL OTHERS (NON MEDICATED PRODUCTS) IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 15 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 16 GLOBAL ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 17 GLOBAL ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 18 GLOBAL TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 19 GLOBAL TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 20 GLOBAL OTHERS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 21 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 22 GLOBAL OVER THE COUNTER IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 23 GLOBAL PRESCRIPTION IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 24 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY STRAIN TYPE, 2022- 2031 (USD THOUSAND)

TABLE 25 GLOBAL HERPES SIMPLEX TYPE 1 VIRUS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031

TABLE 26 GLOBAL HERPES SIMPLEX TYPE 2 VIRUS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031

TABLE 27 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY DRUG TYPE, 2022- 2031 (USD THOUSAND)

TABLE 28 GLOBAL GENERIC IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031

TABLE 29 GLOBAL BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031

TABLE 30 GLOBAL BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031

TABLE 31 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY POPULATION TYPE, 2022- 2031 (USD THOUSAND)

TABLE 32 GLOBAL ADULTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031

TABLE 33 GLOBAL PEDIATRICS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031

TABLE 34 GLOBAL GERIATRICS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031

TABLE 35 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY GENDER, 2022- 2031 (USD THOUSAND)

TABLE 36 GLOBAL FEMALE IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031

TABLE 37 GLOBAL MALE IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031

TABLE 38 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY END USER, 2022- 2031 (USD THOUSAND)

TABLE 39 GLOBAL HOME HEALTHCARE IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031

TABLE 40 GLOBAL HOSPITALS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031

TABLE 41 GLOBAL SPECIALTY CLINICS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031

TABLE 42 GLOBAL OTHERS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031

TABLE 43 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022- 2031 (USD THOUSAND)

TABLE 44 GLOBAL DIRECT TENDERS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031

TABLE 45 GLOBAL RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031

TABLE 46 GLOBAL RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031

TABLE 47 GLOBAL OTHERS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031

TABLE 48 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 49 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)

TABLE 50 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 51 NORTH AMERICA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 52 NORTH AMERICA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 53 NORTH AMERICA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 54 NORTH AMERICA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 55 NORTH AMERICA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 56 NORTH AMERICA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 57 NORTH AMERICA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 58 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 59 NORTH AMERICA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 60 NORTH AMERICA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 61 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 62 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 63 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 64 NORTH AMERICA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 65 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 66 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 67 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 68 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 69 NORTH AMERICA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 70 U.S. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 71 U.S. MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 72 U.S. ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 73 U.S. ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 74 U.S. APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 75 U.S. BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 76 U.S. APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 77 U.S. COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 78 U.S. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 79 U.S. ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 80 U.S. TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 81 U.S. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 82 U.S. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 83 U.S. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 84 U.S. BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 85 U.S. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 86 U.S. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 87 U.S. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 88 U.S. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 89 U.S. RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 90 CANADA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 91 CANADA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 92 CANADA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 93 CANADA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 94 CANADA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 95 CANADA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 96 CANADA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 97 CANADA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 98 CANADA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 99 CANADA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 100 CANADA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 101 CANADA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 102 CANADA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 103 CANADA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 104 CANADA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 105 CANADA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 106 CANADA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 107 CANADA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 108 CANADA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 109 CANADA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 110 MEXICO COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 111 MEXICO MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 112 MEXICO ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 113 MEXICO ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 114 MEXICO APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 115 MEXICO BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 116 MEXICO APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 117 MEXICO COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 118 MEXICO COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 119 MEXICO ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 120 MEXICO TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 121 MEXICO COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 122 MEXICO COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 123 MEXICO COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 124 MEXICO BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 125 MEXICO COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 126 MEXICO COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 127 MEXICO COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 128 MEXICO COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 129 MEXICO RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 130 EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)

TABLE 131 EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 132 EUROPE MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 133 EUROPE ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 134 EUROPE ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 135 EUROPE APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 136 EUROPE BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 137 EUROPE APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 138 EUROPE COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 139 EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 140 EUROPE ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 141 EUROPE TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 142 EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 143 EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 144 EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 145 EUROPE BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 146 EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 147 EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 148 EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 149 EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 150 EUROPE RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 151 GERMANY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 152 GERMANY MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 153 GERMANY ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 154 GERMANY ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 155 GERMANY APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 156 GERMANY BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 157 GERMANY APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 158 GERMANY COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 159 GERMANY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 160 GERMANY ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 161 GERMANY TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 162 GERMANY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 163 GERMANY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 164 GERMANY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 165 GERMANY BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 166 GERMANY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 167 GERMANY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 168 GERMANY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 169 GERMANY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 170 GERMANY RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 171 FRANCE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 172 FRANCE MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 173 FRANCE ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 174 FRANCE ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 175 FRANCE APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 176 FRANCE BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 177 FRANCE APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 178 FRANCE COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 179 FRANCE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 180 FRANCE ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 181 FRANCE TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 182 FRANCE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 183 FRANCE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 184 FRANCE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 185 FRANCE BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 186 FRANCE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 187 FRANCE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 188 FRANCE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 189 FRANCE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 190 FRANCE RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 191 U.K. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 192 U.K. MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 193 U.K. ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 194 U.K. ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 195 U.K. APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 196 U.K. BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 197 U.K. APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 198 U.K. COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 199 U.K. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 200 U.K. ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 201 U.K. TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 202 U.K. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 203 U.K. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 204 U.K. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 205 U.K. BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 206 U.K. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 207 U.K. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 208 U.K. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 209 U.K. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 210 U.K. RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 211 ITALY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 212 ITALY MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 213 ITALY ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 214 ITALY ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 215 ITALY APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 216 ITALY BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 217 ITALY APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 218 ITALY COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 219 ITALY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 220 ITALY ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 221 ITALY TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 222 ITALY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 223 ITALY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 224 ITALY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 225 ITALY BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 226 ITALY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 227 ITALY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 228 ITALY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 229 ITALY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 230 ITALY RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 231 SPAIN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 232 SPAIN MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 233 SPAIN ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 234 SPAIN ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 235 SPAIN APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 236 SPAIN BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 237 SPAIN APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 238 SPAIN COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 239 SPAIN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 240 SPAIN ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 241 SPAIN TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 242 SPAIN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 243 SPAIN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 244 SPAIN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 245 SPAIN BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 246 SPAIN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 247 SPAIN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 248 SPAIN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 249 SPAIN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 250 SPAIN RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 251 RUSSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 252 RUSSIA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 253 RUSSIA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 254 RUSSIA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 255 RUSSIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 256 RUSSIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 257 RUSSIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 258 RUSSIA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 259 RUSSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 260 RUSSIA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 261 RUSSIA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 262 RUSSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 263 RUSSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 264 RUSSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 265 RUSSIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 266 RUSSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 267 RUSSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 268 RUSSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 269 RUSSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 270 RUSSIA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 271 SWITZERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 272 SWITZERLAND MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 273 SWITZERLAND ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 274 SWITZERLAND ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 275 SWITZERLAND APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 276 SWITZERLAND BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 277 SWITZERLAND APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 278 SWITZERLAND COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 279 SWITZERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 280 SWITZERLAND ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 281 SWITZERLAND TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 282 SWITZERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 283 SWITZERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 284 SWITZERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 285 SWITZERLAND BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 286 SWITZERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 287 SWITZERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 288 SWITZERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 289 SWITZERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 290 SWITZERLAND RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 291 NETHERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 292 NETHERLAND MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 293 NETHERLAND ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 294 NETHERLAND ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 295 NETHERLAND APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 296 NETHERLAND BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 297 NETHERLAND APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 298 NETHERLAND COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 299 NETHERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 300 NETHERLAND ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 301 NETHERLAND TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 302 NETHERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 303 NETHERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 304 NETHERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 305 NETHERLAND BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 306 NETHERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 307 NETHERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 308 NETHERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 309 NETHERLAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 310 NETHERLAND RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 311 TURKEY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 312 TURKEY MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 313 TURKEY ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 314 TURKEY ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 315 TURKEY APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 316 TURKEY BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 317 TURKEY APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 318 TURKEY COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 319 TURKEY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 320 TURKEY ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 321 TURKEY TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 322 TURKEY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 323 TURKEY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 324 TURKEY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 325 TURKEY BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 326 TURKEY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 327 TURKEY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 328 TURKEY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 329 TURKEY COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 330 TURKEY RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 331 BELGIUM COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 332 BELGIUM MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 333 BELGIUM ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 334 BELGIUM ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 335 BELGIUM APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 336 BELGIUM BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 337 BELGIUM APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 338 BELGIUM COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 339 BELGIUM COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 340 BELGIUM ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 341 BELGIUM TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 342 BELGIUM COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 343 BELGIUM COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 344 BELGIUM COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 345 BELGIUM BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 346 BELGIUM COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 347 BELGIUM COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 348 BELGIUM COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 349 BELGIUM COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 350 BELGIUM RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 351 REST OF EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 352 ASIA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)

TABLE 353 ASIA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 354 ASIA-PACIFIC MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 355 ASIA-PACIFIC ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 356 ASIA-PACIFIC ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 357 ASIA-PACIFIC APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 358 ASIA-PACIFIC BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 359 ASIA-PACIFIC APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 360 ASIA-PACIFIC COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 361 ASIA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 362 ASIA-PACIFIC ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 363 ASIA-PACIFIC TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 364 ASIA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 365 ASIA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 366 ASIA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 367 ASIA-PACIFIC BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 368 ASIA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 369 ASIA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 370 ASIA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 371 ASIA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 372 ASIA-PACIFIC RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 373 CHINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 374 CHINA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 375 CHINA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 376 CHINA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 377 CHINA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 378 CHINA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 379 CHINA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 380 CHINA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 381 CHINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 382 CHINA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 383 CHINA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 384 CHINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 385 CHINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 386 CHINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 387 CHINA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 388 CHINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 389 CHINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 390 CHINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 391 CHINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 392 CHINA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 393 JAPAN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 394 JAPAN MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 395 JAPAN ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 396 JAPAN ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 397 JAPAN APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 398 JAPAN BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 399 JAPAN APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 400 JAPAN COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 401 JAPAN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 402 JAPAN ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 403 JAPAN TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 404 JAPAN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 405 JAPAN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 406 JAPAN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 407 JAPAN BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 408 JAPAN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 409 JAPAN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 410 JAPAN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 411 JAPAN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 412 JAPAN RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 413 INDIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 414 INDIA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 415 INDIA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 416 INDIA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 417 INDIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 418 INDIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 419 INDIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 420 INDIA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 421 INDIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 422 INDIA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 423 INDIA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 424 INDIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 425 INDIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 426 INDIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 427 INDIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 428 INDIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 429 INDIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 430 INDIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 431 INDIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 432 INDIA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 433 AUSTRALIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 434 AUSTRALIA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 435 AUSTRALIA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 436 AUSTRALIA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 437 AUSTRALIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 438 AUSTRALIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 439 AUSTRALIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 440 AUSTRALIA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 441 AUSTRALIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 442 AUSTRALIA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 443 AUSTRALIA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 444 AUSTRALIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 445 AUSTRALIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 446 AUSTRALIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 447 AUSTRALIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 448 AUSTRALIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 449 AUSTRALIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 450 AUSTRALIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 451 AUSTRALIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 452 AUSTRALIA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 453 SOUTH KOREA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 454 SOUTH KOREA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 455 SOUTH KOREA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 456 SOUTH KOREA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 457 SOUTH KOREA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 458 SOUTH KOREA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 459 SOUTH KOREA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 460 SOUTH KOREA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 461 SOUTH KOREA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 462 SOUTH KOREA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 463 SOUTH KOREA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 464 SOUTH KOREA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 465 SOUTH KOREA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 466 SOUTH KOREA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 467 SOUTH KOREA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 468 SOUTH KOREA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 469 SOUTH KOREA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 470 SOUTH KOREA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 471 SOUTH KOREA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 472 SOUTH KOREA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 473 SINGAPORE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 474 SINGAPORE MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 475 SINGAPORE ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 476 SINGAPORE ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 477 SINGAPORE APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 478 SINGAPORE BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 479 SINGAPORE APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 480 SINGAPORE COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 481 SINGAPORE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 482 SINGAPORE ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 483 SINGAPORE TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 484 SINGAPORE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 485 SINGAPORE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 486 SINGAPORE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 487 SINGAPORE BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 488 SINGAPORE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 489 SINGAPORE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 490 SINGAPORE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 491 SINGAPORE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 492 SINGAPORE RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 493 MALAYSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 494 MALAYSIA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 495 MALAYSIA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 496 MALAYSIA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 497 MALAYSIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 498 MALAYSIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 499 MALAYSIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 500 MALAYSIA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 501 MALAYSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 502 MALAYSIA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 503 MALAYSIA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 504 MALAYSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 505 MALAYSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 506 MALAYSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 507 MALAYSIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 508 MALAYSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 509 MALAYSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 510 MALAYSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 511 MALAYSIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 512 MALAYSIA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 513 PHILIPPINES COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 514 PHILIPPINES MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 515 PHILIPPINES ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 516 PHILIPPINES ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 517 PHILIPPINES APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 518 PHILIPPINES BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 519 PHILIPPINES APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 520 PHILIPPINES COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 521 PHILIPPINES COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 522 PHILIPPINES ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 523 PHILIPPINES TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 524 PHILIPPINES COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 525 PHILIPPINES COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 526 PHILIPPINES COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 527 PHILIPPINES BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 528 PHILIPPINES COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 529 PHILIPPINES COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 530 PHILIPPINES COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 531 PHILIPPINES COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 532 PHILIPPINES RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 533 INDONESIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 534 INDONESIA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 535 INDONESIA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 536 INDONESIA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 537 INDONESIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 538 INDONESIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 539 INDONESIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 540 INDONESIA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 541 INDONESIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 542 INDONESIA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 543 INDONESIA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 544 INDONESIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 545 INDONESIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 546 INDONESIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 547 INDONESIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 548 INDONESIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 549 INDONESIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 550 INDONESIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 551 INDONESIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 552 INDONESIA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 553 THAILAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 554 THAILAND MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 555 THAILAND ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 556 THAILAND ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 557 THAILAND APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 558 THAILAND BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 559 THAILAND APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 560 THAILAND COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 561 THAILAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 562 THAILAND ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 563 THAILAND TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 564 THAILAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 565 THAILAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 566 THAILAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 567 THAILAND BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 568 THAILAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 569 THAILAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 570 THAILAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 571 THAILAND COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 572 THAILAND RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 573 REST OF ASIA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 574 SOUTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)

TABLE 575 SOUTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 576 SOUTH AMERICA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 577 SOUTH AMERICA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 578 SOUTH AMERICA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 579 SOUTH AMERICA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 580 SOUTH AMERICA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 581 SOUTH AMERICA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 582 SOUTH AMERICA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 583 SOUTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 584 SOUTH AMERICA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 585 SOUTH AMERICA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 586 SOUTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 587 SOUTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 588 SOUTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 589 SOUTH AMERICA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 590 SOUTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 591 SOUTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 592 SOUTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 593 SOUTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 594 SOUTH AMERICA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 595 BRAZIL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 596 BRAZIL MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 597 BRAZIL ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 598 BRAZIL ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 599 BRAZIL APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 600 BRAZIL BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 601 BRAZIL APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 602 BRAZIL COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 603 BRAZIL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 604 BRAZIL ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 605 BRAZIL TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 606 BRAZIL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 607 BRAZIL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 608 BRAZIL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 609 BRAZIL BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 610 BRAZIL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 611 BRAZIL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 612 BRAZIL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 613 BRAZIL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 614 BRAZIL RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 615 ARGENTINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 616 ARGENTINA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 617 ARGENTINA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 618 ARGENTINA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 619 ARGENTINA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 620 ARGENTINA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 621 ARGENTINA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 622 ARGENTINA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 623 ARGENTINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 624 ARGENTINA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 625 ARGENTINA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 626 ARGENTINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 627 ARGENTINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 628 ARGENTINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 629 ARGENTINA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 630 ARGENTINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 631 ARGENTINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 632 ARGENTINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 633 ARGENTINA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 634 ARGENTINA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 635 REST OF SOUTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 636 MIDDLE EAST AND AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)

TABLE 637 MIDDLE EAST AND AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 638 MIDDLE EAST AND AFRICA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 639 MIDDLE EAST AND AFRICA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 640 MIDDLE EAST AND AFRICA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 641 MIDDLE EAST AND AFRICA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 642 MIDDLE EAST AND AFRICA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 643 MIDDLE EAST AND AFRICA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 644 MIDDLE EAST AND AFRICA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 645 MIDDLE EAST AND AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 646 MIDDLE EAST AND AFRICA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 647 MIDDLE EAST AND AFRICA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 648 MIDDLE EAST AND AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 649 MIDDLE EAST AND AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 650 MIDDLE EAST AND AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 651 MIDDLE EAST AND AFRICA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 652 MIDDLE EAST AND AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 653 MIDDLE EAST AND AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 654 MIDDLE EAST AND AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 655 MIDDLE EAST AND AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 656 MIDDLE EAST AND AFRICA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 657 SOUTH AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 658 SOUTH AFRICA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 659 SOUTH AFRICA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 660 SOUTH AFRICA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 661 SOUTH AFRICA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 662 SOUTH AFRICA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 663 SOUTH AFRICA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 664 SOUTH AFRICA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 665 SOUTH AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 666 SOUTH AFRICA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 667 SOUTH AFRICA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 668 SOUTH AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 669 SOUTH AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 670 SOUTH AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 671 SOUTH AFRICA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 672 SOUTH AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 673 SOUTH AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 674 SOUTH AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 675 SOUTH AFRICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 676 SOUTH AFRICA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 677 EGYPT COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 678 EGYPT MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 679 EGYPT ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 680 EGYPT ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 681 EGYPT APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 682 EGYPT BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 683 EGYPT APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 684 EGYPT COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 685 EGYPT COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 686 EGYPT ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 687 EGYPT TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 688 EGYPT COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 689 EGYPT COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 690 EGYPT COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 691 EGYPT BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 692 EGYPT COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 693 EGYPT COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 694 EGYPT COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 695 EGYPT COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 696 EGYPT RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 697 SAUDI ARABIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 698 SAUDI ARABIA MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 699 SAUDI ARABIA ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 700 SAUDI ARABIA ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 701 SAUDI ARABIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 702 SAUDI ARABIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 703 SAUDI ARABIA APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 704 SAUDI ARABIA COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 705 SAUDI ARABIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 706 SAUDI ARABIA ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 707 SAUDI ARABIA TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 708 SAUDI ARABIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 709 SAUDI ARABIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 710 SAUDI ARABIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 711 SAUDI ARABIA BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 712 SAUDI ARABIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 713 SAUDI ARABIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 714 SAUDI ARABIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 715 SAUDI ARABIA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 716 SAUDI ARABIA RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 717 U.A.E. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 718 U.A.E. MEDICATIONS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 719 U.A.E. ANTIVIRAL AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 720 U.A.E. ANALGESIC AGENTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 721 U.A.E. APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 722 U.A.E. BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 723 U.A.E. APPLIED PRODUCTS IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY CATEGORY, 2022-2031 (USD THOUSAND)

TABLE 724 U.A.E. COLD SORE PATCHES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 725 U.A.E. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 726 U.A.E. ORAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 727 U.A.E. TOPICAL IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 728 U.A.E. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY MODE OF PURCHASE, 2022-2031 (USD THOUSAND)

TABLE 729 U.A.E. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY STRAIN TYPE, 2022-2031 (USD THOUSAND)

TABLE 730 U.A.E. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 731 U.A.E. BRANDED IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 732 U.A.E. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 733 U.A.E. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER, 2022-2031 (USD THOUSAND)

TABLE 734 U.A.E. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 735 U.A.E. COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 736 U.A.E. RETAIL SALES IN COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

Abbildungsverzeichnis

FIGURE 1 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: SEGMENTATION

FIGURE 2 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: DATA TRIANGULATION

FIGURE 3 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: DROC ANALYSIS

FIGURE 4 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 8 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: DBMR MARKET POSITION GRID

FIGURE 9 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: SEGMENTATION

FIGURE 11 GROWING PREVALENCE OF COLD SORE INFECTION IS DRIVING THE GROWTH OF THE GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET FROM 2024 TO 2031

FIGURE 12 THE TREATMENT TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET IN 2024 AND 2031

FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2024 TO 2031

FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING REGION FOR COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET MANUFACTURERS IN THE FORECAST PERIOD OF 2024 TO 2031

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET

FIGURE 16 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY TREATMENT TYPE, 2023

FIGURE 17 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY TREATMENT TYPE, 2024-2031 (USD THOUSAND)

FIGURE 18 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY TREATMENT TYPE, CAGR (2024-2031)

FIGURE 19 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY TREATMENT TYPE, LIFELINE CURVE

FIGURE 20 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY ROUTE OF ADMINISTRATION, 2023

FIGURE 21 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY ROUTE OF ADMINISTRATION, 2024-2031 (USD THOUSAND)

FIGURE 22 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY ROUTE OF ADMINISTRATION, CAGR (2024-2031)

FIGURE 23 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 24 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY MODE OF PURCHASE, 2023

FIGURE 25 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY MODE OF PURCHASE, 2024-2031 (USD THOUSAND)

FIGURE 26 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY MODE OF PURCHASE, CAGR (2024-2031)

FIGURE 27 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET : BY MODE OF PURCHASE, LIFELINE CURVE

FIGURE 28 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY STRAIN TYPE, 2023

FIGURE 29 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY STRAIN TYPE, 2024-2031 (USD THOUSAND)

FIGURE 30 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY STRAIN TYPE, CAGR (2024-2031)

FIGURE 31 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY STRAIN TYPE, LIFELINE CURVE

FIGURE 32 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY DRUG TYPE, 2023

FIGURE 33 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY DRUG TYPE, 2024-2031 (USD THOUSAND)

FIGURE 34 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY DRUG TYPE, CAGR (2024-2031)

FIGURE 35 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY DRUG TYPE, LIFELINE CURVE

FIGURE 36 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY POPULATION TYPE, 2023

FIGURE 37 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY POPULATION TYPE, 2024-2031 (USD THOUSAND)

FIGURE 38 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY POPULATION TYPE, CAGR (2024-2031)

FIGURE 39 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY POPULATION TYPE, LIFELINE CURVE

FIGURE 40 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY GENDER, 2023

FIGURE 41 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY GENDER, 2024-2031 (USD THOUSAND)

FIGURE 42 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY GENDER, CAGR (2024-2031)

FIGURE 43 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY GENDER, LIFELINE CURVE

FIGURE 44 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY END USER, 2023

FIGURE 45 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY END USER, 2024-2031 (USD THOUSAND)

FIGURE 46 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY END USER, CAGR (2024-2031)

FIGURE 47 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY END USER, LIFELINE CURVE

FIGURE 48 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY DISTRIBUTION CHANNEL, 2023

FIGURE 49 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD THOUSAND)

FIGURE 50 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)

FIGURE 51 GLOBAL COLD SORE TREATMENT (FOR HSV1 VIRUS) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 52 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: SNAPSHOT (2023)

FIGURE 53 GLOBAL COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: COMPANY SHARE 2023 (%)

FIGURE 54 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: COMPANY SHARE 2023 (%)

FIGURE 55 EUROPE COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: COMPANY SHARE 2023 (%)

FIGURE 56 AISA-PACIFIC COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: COMPANY SHARE 2023 (%)

Detaillierte Informationen anzeigen Right Arrow

Forschungsmethodik

Die Datenerfassung und Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Phase umfasst das Erhalten von Marktinformationen oder verwandten Daten aus verschiedenen Quellen und Strategien. Sie umfasst die Prüfung und Planung aller aus der Vergangenheit im Voraus erfassten Daten. Sie umfasst auch die Prüfung von Informationsinkonsistenzen, die in verschiedenen Informationsquellen auftreten. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Um mehr zu erfahren, fordern Sie bitte einen Analystenanruf an oder geben Sie Ihre Anfrage ein.

Die wichtigste Forschungsmethodik, die vom DBMR-Forschungsteam verwendet wird, ist die Datentriangulation, die Data Mining, die Analyse der Auswirkungen von Datenvariablen auf den Markt und die primäre (Branchenexperten-)Validierung umfasst. Zu den Datenmodellen gehören ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, ein Marktüberblick und -leitfaden, ein Firmenpositionierungsraster, eine Patentanalyse, eine Preisanalyse, eine Firmenmarktanteilsanalyse, Messstandards, eine globale versus eine regionale und Lieferantenanteilsanalyse. Um mehr über die Forschungsmethodik zu erfahren, senden Sie eine Anfrage an unsere Branchenexperten.

Anpassung möglich

Data Bridge Market Research ist ein führendes Unternehmen in der fortgeschrittenen formativen Forschung. Wir sind stolz darauf, unseren bestehenden und neuen Kunden Daten und Analysen zu bieten, die zu ihren Zielen passen. Der Bericht kann angepasst werden, um Preistrendanalysen von Zielmarken, Marktverständnis für zusätzliche Länder (fordern Sie die Länderliste an), Daten zu klinischen Studienergebnissen, Literaturübersicht, Analysen des Marktes für aufgearbeitete Produkte und Produktbasis einzuschließen. Marktanalysen von Zielkonkurrenten können von technologiebasierten Analysen bis hin zu Marktportfoliostrategien analysiert werden. Wir können so viele Wettbewerber hinzufügen, wie Sie Daten in dem von Ihnen gewünschten Format und Datenstil benötigen. Unser Analystenteam kann Ihnen auch Daten in groben Excel-Rohdateien und Pivot-Tabellen (Fact Book) bereitstellen oder Sie bei der Erstellung von Präsentationen aus den im Bericht verfügbaren Datensätzen unterstützen.

Häufig gestellte Fragen

The Cold Sore Treatment (for HSV 1 Virus) Market size will be worth USD 1,501.88 million by 2031.
The Cold Sore Treatment (for HSV 1 Virus) Market growth rate will be 6.6% by 2031.
Growing Prevalence of Cold Sore Infection and Growing Awareness about Cold Sore Symptoms and Treatment Options are the growth drivers of the Cold Sore Treatment (for HSV 1 Virus) Market.
The treatment type, route of administration, mode of purchase, strain type, drug type, population type, gender, end user, and distribution channel are the factors on which the Cold Sore Treatment (for HSV 1 Virus) Market research is based.
The major companies in the Cold Sore Treatment (for HSV 1 Virus) Market are Fresenius SE & Co. KGaA, Zydus Pharmaceuticals, Inc., Teva Pharmaceuticals Industries Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Quantum Health, GSK plc., Haleon Group of Companies, Church & Dwight Co., Inc., Hikma Pharmaceuticals PLC, Viatris Inc., Carma Labs Inc., URGO MEDICAL, Apotex Inc., Amneal Pharmaceuticals LLC, Blistex Inc., FOCUS CONSUMER HEALTHCARE, Hetero Healthcare Limited, Amparo medical Technologies, and Devirex AG.

Verwandte Seiten durchsuchen

Banner